Our preclinical findings, however, do suggest that increased expression of EGFR ligands such as amphiregulin, TGF-α, epiregulin, or NRG1 may also be associated with sensitivity to lapatinib in endometrial cancer. Here, AREG is linked to endometrial cancer.